Observational studyJournal of the American Society of Nephrology : JASN2017
Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
Observational study in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 112 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Randomized Controlled Trial of Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of Idiopathic Membranous Nephropathy
Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective Cohort
Who cites it
112 citing papers in PubMed, 11 syntheses or guidelines pooled it, 186 citations in OpenAlex.
- Comparative efficacy and safety of rituximab versus cyclophosphamide with steroids in primary membranous nephropathy: a systematic review and meta-analysis.BMC nephrology · 2026Pooled it
- Evaluating rituximab against cyclophosphamide or cyclosporine in idiopathic membranous nephropathy: a meta-analysis.European journal of medical research · 2025Pooled it
- Efficacy and safety of Chinese herbal medicines combined with biomedicine in the treatment of idiopathic membranous nephropathy: a systematic review and network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Efficacy and safety of glucocorticoid combined with cyclophosphamide therapy on membranous nephropathy: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels.BMC nephrology · 2023Pooled it
- Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.International urology and nephrology · 2023Pooled it
- Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis.International journal of clinical practice · 2022Pooled it
- Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis.International urology and nephrology · 2021Pooled it
- The efficacy of rituximab in the treatment of refractory nephrotic syndrome: a meta-analysis.International urology and nephrology · 2020Pooled it
- Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population.Drug design, development and therapy · 2019Pooled it
- Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.Renal failure · 2020Trial
- Rituximab vs. cyclophosphamide in treatment-naive IMN: efficacy and renal protection in early renal impairment.Clinical and experimental nephrology · 2026Article
- Comparison of efficacy and safety among four therapeutic regimens in primary membranous nephropathy with high anti-PLA2R antibody titers: a single-center retrospective cohort study.BMC nephrology · 2026Article
- Retrospective study of treatment effectiveness and remission predictors of obinutuzumab in primary membranous nephropathy.BMC nephrology · 2026Article
- Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy.Kidney international reports · 2026Article
- Efficacy and safety of scheduled rituximab in children with refractory nephrotic syndrome after multi-target therapy failure.Pediatric nephrology (Berlin, Germany) · 2026Article
- [Primary glomerulonephritides].Innere Medizin (Heidelberg, Germany) · 2026Article
- Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy.Kidney international reports · 2026Article
- Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guidelines recommend steroid plus cyclical cyclophosphamide (St-Cp) therapy for patients with idiopathic membranous nephropathy at high risk of progression to ESRD. Rituximab (Rtx) may be a safer alternative. In this retrospective, observational cohort study, we compared time to any adverse event (primary outcome); serious or nonserious events; partial and complete remission of the nephrotic syndrome; and a composite of doubling of serum creatinine, ESRD, or death between 100 Rtx-treated patients and 103 patients who received daily St-Cp We monitored patients with standardized protocols and adjusted for baseline characteristics by Cox regression. Over a median follow-up of 40 months, the Rtx group had significantly fewer adverse events than the St-Cp group (63 versus 173;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.